心房颤动混合消融:微创外科与经皮导管联合治疗
混合消融联合微创外科与经皮导管技术,用于房颤有创管理。证据主要来自经验中心观察性研究,成功率约70%,风险为导管消融的2.0至3.6倍。一项随机试验显示混合消融优于导管消融但并发症更高。目前建议经验中心对选择性持续或长程持续房颤患者实施。
要点
- 混合消融成功率约70%,风险为导管消融的2.0至3.6倍。
- 一项随机试验示混合消融更有效但并发症率更高。
- 适用于经验中心选择性持续或长程持续房颤患者。
核心结论
- 混合消融对选择性持续或长程持续房颤患者有效,但风险高于导管消融,需经验中心实施。
研究设计与样本
- 综述基于观察性研究和一项随机试验,证据主要来自经验中心。
主要发现
- 混合消融成功率约70%,风险为导管消融的2.0至3.6倍。
- 一项随机试验显示混合消融比导管消融更有效,但并发症率更高。
- 近期研究中混合消融最严重并发症发生率已下降。
关键数值与推荐
- 混合消融通常用于持续或长程持续房颤患者,设计上需两次手术(心外膜外科和心内膜导管消融)。
临床怎么用
- 目前应在经验中心对选择性持续或长程持续房颤患者实施混合消融。
局限性
- 证据主要基于观察性研究,需更多随机试验明确风险、获益和成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hybrid ablation is a novel therapy in the invasive management of patients with atrial fibrillation (AF) which combines minimally invasive surgical and percutaneous catheter-based techniques. The evidence is mainly based on observational studies from experienced centers, with success rates of approximately 70% and risks that are 2.0-fold to 3.6-fold higher than catheter-based ablation. Hybrid ablation is offered typically to patients with persistent or longstanding persistent AF which, by design, requires 2 procedures (epicardial surgical and endocardial catheter-based ablation). One randomized trial demonstrated that hybrid ablation was more effective than catheter-based ablation, but with higher complication rates. The incidence of the most serious complications has decreased in contemporary studies of hybrid ablation. At present, hybrid ablation should be performed by experienced centers on selected patients with persistent or longstanding persistent AF. Additional randomized trials are needed to define the risks, benefits, and cost effectiveness of hybrid ablation to identify its most appropriate application in clinical practice.
引用
- Bisleri G, Pandey AK, Verma S, et al. Combined Minimally Invasive Surgical and Percutaneous Catheter Ablation of Atrial Fibrillation: JACC Review Topic of the Week. J Am Coll Cardiol. 2023. PMID: 36754519. doi:10.1016/j.jacc.2022.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。